Kathryn F Mileham MD FACP, FASCO

Chief, Section of Thoracic Medical Oncology; Levine Cancer Institute/Wake Forest Baptist Comprehensive Cancer Center/Atrium Health

Join to view full profile

1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000

Dr. Mileham is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mileham's full profile Already have an account?

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Vanderbilt University Medical CenterResidency, Internal Medicine, 2003 - 2006
Medical University of South CarolinaClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NC State Medical License 2009 - 2027
TN State Medical License 2006 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2013-2014, 2017

Clinical Trials

Early Diagnosis of Pulmonary Nodules Start of enrollment: 2012 Oct 01
Completed
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer Start of enrollment: 2014 Dec 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Pertuzumab and Trastuzumab in Patients With-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.
John K Chan, Michael Rothe, Elizabeth Garrett-Mayer, Evan Pisick, Pooja Ghatalia
JCO Precision Oncology. 2026-04-01
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
Erin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, Timothy L Cannon, John K Chan
JCO Precision Oncology. 2026-04-01
Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.
Kathryn F Mileham, Laura Panattoni, Grace Gahlon, Pedro Labisa, Nicole Bariahtaris
Future Oncology. 2025-12-01

Lectures

Effectiveness of ASCOâ€™s adverse event reporting decision aid: Results from an interventional study.
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Moving Away (Finally) from Doublet Therapy in Lung Cancer: Immunotherapy and KEYNOTE-189September 2018

Press Mentions

COVID-19 Mortality Risk Higher Among Older Patients with B-cell MalignanciesJanuary 6th, 2022
GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung CancerDecember 21st, 2021
Targeted Therapy for Mutation-Driven Metastatic Non–Small-Cell Lung Cancer: Considerations for ALK-Rearranged TumorsApril 15th, 2019